Alistair Ring
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alistair Ring has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
A Jones
Department of Academic Oncology, Royal Free Hospital, Pond Street, London NW3 2QG, UK
1 shared publicationA. Webb
Sussex Cancer Centre, Royal Sussex County Hospital, Brighton
1 shared publicationAman Buzdar
1 shared publication- Anthony Howell
University of Manchester, Manchester, UK
1 shared publication - Christopher Coyle
MRC Clinical Trials Unit at UCL, London, UK
1 shared publication Claire L. Watkins
Macclesfield
1 shared publication
Latest Publications
- 13 June 2013
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 67 (7) , 698-700
Breast cancer in older patients: national cancer registry data
Background The population in developed countries is ageing. Cancer is a disease of ageing, and this is likely to lead to an increase in the number of older patients diagnosed with cancer with significant implications for resource allocation and research priorities. Breast Cancer in older women presents a number of challenges. Aims This paper describes the trends in number of new breast cancer registrations in older patients over the last 38 years. Materials and methods Data were extracted from the Office for National Statistics describing new registrations of breast cancer for patients aged 65 or over, from 1971 to 2009. Results The number of diagnoses of breast cancer across all age groups increased from 17,694 in 1971 to 40,260 in 2009. The proportion of diagnoses of breast cancer made in women aged 65 and over increased from 42% in 1971 to 45% in 2009. The proportion of diagnoses of breast cancer made in women aged 70 and over increased from 30% in 1971 to 33% in 2009. The number of cases of breast cancer registered in patients aged 65 and over has increased from 7376 in 1971 to 17,934 in 2009. Discussion The reasons for the large increases in the number of older women diagnosed with breast cancer, and older women represent an increasing proportion of those diagnosed are multi-factorial. These include the ageing of the population, obesity, alcohol consumption, use of hormone replacement therapy and reproductive factors, improved breast cancer awareness and the UK National Screening Programme. Clinician attitudes and behaviours and also cancer registries striving to increase their levels are other causes. The effective management of these women will present constraints to service delivery and should therefore influence research priorities. Conclusion This short communication reports on the increasing registration of breast cancer in the older age group which will present a number of challenges for the future.
- 13 June 2013
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 67 (7) , 698-700
Breast cancer in older patients: national cancer registry data
Background The population in developed countries is ageing. Cancer is a disease of ageing, and this is likely to lead to an increase in the number of older patients diagnosed with cancer with significant implications for resource allocation and research priorities. Breast Cancer in older women presents a number of challenges. Aims This paper describes the trends in number of new breast cancer registrations in older patients over the last 38 years. Materials and methods Data were extracted from the Office for National Statistics describing new registrations of breast cancer for patients aged 65 or over, from 1971 to 2009. Results The number of diagnoses of breast cancer across all age groups increased from 17,694 in 1971 to 40,260 in 2009. The proportion of diagnoses of breast cancer made in women aged 65 and over increased from 42% in 1971 to 45% in 2009. The proportion of diagnoses of breast cancer made in women aged 70 and over increased from 30% in 1971 to 33% in 2009. The number of cases of breast cancer registered in patients aged 65 and over has increased from 7376 in 1971 to 17,934 in 2009. Discussion The reasons for the large increases in the number of older women diagnosed with breast cancer, and older women represent an increasing proportion of those diagnosed are multi-factorial. These include the ageing of the population, obesity, alcohol consumption, use of hormone replacement therapy and reproductive factors, improved breast cancer awareness and the UK National Screening Programme. Clinician attitudes and behaviours and also cancer registries striving to increase their levels are other causes. The effective management of these women will present constraints to service delivery and should therefore influence research priorities. Conclusion This short communication reports on the increasing registration of breast cancer in the older age group which will present a number of challenges for the future.
- 10 November 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (32) , 4266-4272
Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial
Purpose The Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized trial in which postmenopausal women with early-stage breast cancer were assigned to receive anastrozole, tamoxifen, or the combination. We have conducted a retrospective analysis to examine the effects of comorbidities and age on treatment received, breast cancer–related mortality, and competing causes of mortality. Patients and Methods The current analyses were based on 10-year median follow-up data in the two monotherapy arms (anastrozole, n = 3,092; tamoxifen, n = 3,094) of the ATAC study. Baseline comorbidities and tumor and treatment characteristics were compared between women age less than 70 years and women age ≥ 70 years. The cumulative incidence of breast cancer–related and non–breast cancer–related mortality was assessed according to age and comorbidities. Results One thousand six hundred sixty-two patients (27%) were age ≥ 70 years at study entry. Older women were more likely to undergo mastectomy...
- 10 November 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (32) , 4266-4272
Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial
Purpose The Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized trial in which postmenopausal women with early-stage breast cancer were assigned to receive anastrozole, tamoxifen, or the combination. We have conducted a retrospective analysis to examine the effects of comorbidities and age on treatment received, breast cancer–related mortality, and competing causes of mortality. Patients and Methods The current analyses were based on 10-year median follow-up data in the two monotherapy arms (anastrozole, n = 3,092; tamoxifen, n = 3,094) of the ATAC study. Baseline comorbidities and tumor and treatment characteristics were compared between women age less than 70 years and women age ≥ 70 years. The cumulative incidence of breast cancer–related and non–breast cancer–related mortality was assessed according to age and comorbidities. Results One thousand six hundred sixty-two patients (27%) were age ≥ 70 years at study entry. Older women were more likely to undergo mastectomy...
- Open Access
- 21 June 2011
- Published by Springer Nature in British Journal of Cancer
- Vol. 105 (2) , 189-193
The treatment of early breast cancer in women over the age of 70
One third of all breast cancers are diagnosed in women aged 70 or over. Older women are a heterogeneous population who are under-represented in clinical trials, and as a result uncertainty can exist as to what represents optimal treatment. This minireview, from an international authorship, summarises the existing evidence surrounding the management of early breast cancer in women aged 70 and over. The use of primary surgery and endocrine therapy, and adjuvant chemotherapy, radiotherapy, endocrine therapy and trastuzumab are discussed. Reference is made to ongoing clinical trials in this area and areas of controversy are highlighted.
- 21 June 2011
- Published by Springer Nature in British Journal of Cancer
- Vol. 105 (2) , 189-193
Open AccessThe treatment of early breast cancer in women over the age of 70
One third of all breast cancers are diagnosed in women aged 70 or over. Older women are a heterogeneous population who are under-represented in clinical trials, and as a result uncertainty can exist as to what represents optimal treatment. This minireview, from an international authorship, summarises the existing evidence surrounding the management of early breast cancer in women aged 70 and over. The use of primary surgery and endocrine therapy, and adjuvant chemotherapy, radiotherapy, endocrine therapy and trastuzumab are discussed. Reference is made to ongoing clinical trials in this area and areas of controversy are highlighted.
- 16 December 2010
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 3 (2) , 73-83
Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists
It has been estimated that up to 3.8% of breast cancers may be diagnosed in women who are pregnant, with an estimated 1 in 3000–3500 deliveries occurring in women with breast cancer. Owing to the lack of large randomized trials available to guide our clinical practice, our decisions regarding adjuvant systemic management are based on retrospective analyses, case reports and a small number of prospective studies. A tailored approach to treatment is required with careful consideration given at all stages to the needs of the mother and risks to the foetus. Management is critically influenced by the stage of pregnancy, especially the first trimester. Anthracycline-based chemotherapy may be administered during the second and third trimesters, with apparently few short-term implications. Limited data shows the taxanes may also be given with few adverse events at these stages. Weekly fractionation regimens may allow closer monitoring of pregnancy with prompt termination of agents, if necessary. Data concerning the long-term risks of systemic anticancer treatment are limited. All stages of patient management should be discussed within a multidisciplinary team and a clear consensus of treatment options communicated to the mother. Delaying chemotherapy until after delivery may be reasonable in some cases, but where the delay is likely to be prolonged, a decision must be made on the basis of risks versus benefits.
- 16 December 2010
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 3 (2) , 73-83
Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists
It has been estimated that up to 3.8% of breast cancers may be diagnosed in women who are pregnant, with an estimated 1 in 3000–3500 deliveries occurring in women with breast cancer. Owing to the lack of large randomized trials available to guide our clinical practice, our decisions regarding adjuvant systemic management are based on retrospective analyses, case reports and a small number of prospective studies. A tailored approach to treatment is required with careful consideration given at all stages to the needs of the mother and risks to the foetus. Management is critically influenced by the stage of pregnancy, especially the first trimester. Anthracycline-based chemotherapy may be administered during the second and third trimesters, with apparently few short-term implications. Limited data shows the taxanes may also be given with few adverse events at these stages. Weekly fractionation regimens may allow closer monitoring of pregnancy with prompt termination of agents, if necessary. Data concerning the long-term risks of systemic anticancer treatment are limited. All stages of patient management should be discussed within a multidisciplinary team and a clear consensus of treatment options communicated to the mother. Delaying chemotherapy until after delivery may be reasonable in some cases, but where the delay is likely to be prolonged, a decision must be made on the basis of risks versus benefits.
- 30 November 2010
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 76 (2) , 127-132
The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer
- 30 November 2010
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 76 (2) , 127-132
The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer
- 7 February 2010
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 18 (5) , 651-655
The treatment of co-morbidities in older patients with metastatic cancer
The purpose of the study was to determine whether older patients with metastatic cancer continue to take medications for the treatment of pre-existing co-morbidities after the diagnosis of metastatic disease. Between November 2008 and June 2009, patients over the age of 65 with metastatic cancer were interviewed. Medical records were reviewed in order to ascertain current medication use and relevant past medical history. Classes of medication of interest were prospectively defined; these were anti-hypertensives, lipid-lowering drugs, anti-platelet agents, anti-coagulants and bisphosphonates. One hundred patients were recruited, with a median age of 73.5 years (range 65–88); 52% were women. The primary cancer sites were breast, 36%; prostate, 27%; colon, 14%; other, 23%. The median performance status of the patients was 2. The median number of medications was 7 (range 1–17). Eighty-one percent of patients were found to be taking one or more of the predefined medications for treatment of a long-term co-morbidity. Overall 52% of patients had side effects attributed to these medications. Patients with metastatic cancer continue to take drugs for prevention of co-morbidities which are associated with side effects and inconvenience. The benefits of these drugs are likely to be minimal, and medication reviews should be undertaken to address their appropriateness.
- 7 February 2010
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 18 (5) , 651-655
The treatment of co-morbidities in older patients with metastatic cancer
The purpose of the study was to determine whether older patients with metastatic cancer continue to take medications for the treatment of pre-existing co-morbidities after the diagnosis of metastatic disease. Between November 2008 and June 2009, patients over the age of 65 with metastatic cancer were interviewed. Medical records were reviewed in order to ascertain current medication use and relevant past medical history. Classes of medication of interest were prospectively defined; these were anti-hypertensives, lipid-lowering drugs, anti-platelet agents, anti-coagulants and bisphosphonates. One hundred patients were recruited, with a median age of 73.5 years (range 65–88); 52% were women. The primary cancer sites were breast, 36%; prostate, 27%; colon, 14%; other, 23%. The median performance status of the patients was 2. The median number of medications was 7 (range 1–17). Eighty-one percent of patients were found to be taking one or more of the predefined medications for treatment of a long-term co-morbidity. Overall 52% of patients had side effects attributed to these medications. Patients with metastatic cancer continue to take drugs for prevention of co-morbidities which are associated with side effects and inconvenience. The benefits of these drugs are likely to be minimal, and medication reviews should be undertaken to address their appropriateness.
- 6 June 2008
- Published by Elsevier in Annals of Oncology
- Vol. 19 (8) , 1509-1510
Infusion of trastuzumab maintenance doses over 30 minutes
The humanized monoclonal antibody trastuzumab is licensed for both the adjuvant treatment of early breast cancer and the palliation of metastatic breast cancer [1]. In the UK, trastuzumab is usually administered on a three weekly schedule. According to the license, it is infused over a period of 90 min and the patient is observed for 4.5 h after the loading dose, and for 30 min after all subsequent maintenance infusions. Prolonged infusion times have been justified by the risk of infusion reactions, with 54% of patients having at least one symptom with their first infusion, usually pyrexia, headache or rigors [2]. Infusion reactions are much less common with maintenance doses, particularly when premedication with steroids or antihistamines is used, and severe reactions to infusions are very rare [2, 3]. On this basis, therefore, some UK centres routinely administer maintenance doses of trastuzumab over 30 min, and this practice has become accepted in some clinical trials where infusion times can be reduced to 30 min if patients have not had a reaction to the loading dose [4].
- 6 June 2008
- Published by Elsevier in Annals of Oncology
- Vol. 19 (8) , 1509-1510
Infusion of trastuzumab maintenance doses over 30 minutes
The humanized monoclonal antibody trastuzumab is licensed for both the adjuvant treatment of early breast cancer and the palliation of metastatic breast cancer [1]. In the UK, trastuzumab is usually administered on a three weekly schedule. According to the license, it is infused over a period of 90 min and the patient is observed for 4.5 h after the loading dose, and for 30 min after all subsequent maintenance infusions. Prolonged infusion times have been justified by the risk of infusion reactions, with 54% of patients having at least one symptom with their first infusion, usually pyrexia, headache or rigors [2]. Infusion reactions are much less common with maintenance doses, particularly when premedication with steroids or antihistamines is used, and severe reactions to infusions are very rare [2, 3]. On this basis, therefore, some UK centres routinely administer maintenance doses of trastuzumab over 30 min, and this practice has become accepted in some clinical trials where infusion times can be reduced to 30 min if patients have not had a reaction to the loading dose [4].
- 1 April 2008
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 1 (2) , 105-113
A Randomized Study of Electronic Diary versus Paper and Pencil Collection of Patient-Reported Outcomes in Patients with Non-Small Cell Lung Cancer
Background:Hand-held electronic devices may provide a simple reproducible means by which quality of life (QOL) may be documented in patients with cancer. However, the QOL scales that are routinely...
- 1 April 2008
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 1 (2) , 105-113
A Randomized Study of Electronic Diary versus Paper and Pencil Collection of Patient-Reported Outcomes in Patients with Non-Small Cell Lung Cancer
Background:Hand-held electronic devices may provide a simple reproducible means by which quality of life (QOL) may be documented in patients with cancer. However, the QOL scales that are routinely...